Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2000-03-03
2002-06-04
Tate, Christopher R. (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
Reexamination Certificate
active
06399058
ABSTRACT:
The present invention is directed to methods for treating ocular diseases by implanting capsules in the eye which contain cells that secrete therapeutic amounts of pharmaceuticals to treat ocular diseases such as glaucoma.
BACKGROUND OF THE INVENTION
Primary open angle glaucoma is a family of ocular diseases with characteristic cupping of the optic nerve head and eventual loss of visual field due to pathological changes at the optic nerve head and retina. One of the several risk factors for glaucoma is an increase in intraocular pressure (IOP). It is generally believed that reduction of TOP by pharmacological agents can delay or prevent the development of glaucomatous optic retinopathy (Perkins, “Treatment of Glaucoma by Lowering Intraocular Pressure,” Glaucoma, (eds.) P. L. Kaufman and T. W. Mittag, Mosby Publishing Co., pp. 9.1-9.6, 1991).
The current invention describes novel methods for the treatment of glaucoma in human patients. These methods, include the implantation into the eye of encapsulated cells that naturally or are bioengineered to secrete continuously appropriate compounds for the treatment of ocular hypertension.
The implantation of capsules containing cells that secrete biologically active molecules is known. For example, WO 95/05452 discloses compositions and methods for delivery of biologically active molecules using genetically altered cells in capsules. WO 95.8166 discloses a method for implanting encapsulated cells in a host, including preparing the cells for implantation by exposing them to the restrictive conditions that match the implantation site. WO 9/0264A2 discloses a method for controlling growth of cells which are encapsulated in a bioartificial organ (BAO). The publication further discloses a method whereby cells are proliferated in vitro and a balance between proliferation and differentiation is controlled when the cells are encapsulated in a BAO. The method allows for regulation of cell numbers in the BAO and, therefore improved regulation of their output. The method also discloses control of the cell location in the BAO thereby reducing undesirable necrotic cell cores in the BAOs. WO94/25503 discloses certain graft polymers for use in the encapsulation of living cells. WO 94/10950 discloses microporous capsules useful as an implantation device for cell therapy. U.S. Pat. No. 5,158,881 discloses a method and system for encapsulating cells within a semipermeable polymeric membrane by co-extruding an aqueous cell suspension and a polymeric solution through a common port to form a tubular extrudate having a polymeric outer coating which encapsulates the cell suspension. U.S. Pat. No. 5,283,187 also discloses a method for encapsulating living cells within a semipermeable polymeric membrane by co-extruding an aqueous cell suspension and a polymeric solution through a common port having at least one concentric bore to form a tubular extrudate having a polymeric membrane which encapsulates the cell suspension. WO 95/01203 discloses an apparatus and method for sealing implantable hollow fiber encapsulation devices.
None of the cited publications disclose the use of the capsules containing secreting cells for implantation into an eye to treat glaucoma.
SUMMARY OF THE INVENTION
This invention relates to novel methods for implanting encapsulated cells in a glaucomatous eye of a patient. The encapsulated cells produce therapeutic amounts of one or more pharmacologically active substances which may be useful in lowering intraocular pressure.
DESCRIPTION OF PREFERRED EMBODIMENTS
The present invention is directed to the use of capsules which are permeable to nutrients, but isolate encapsulated cells from the immune defense systems of its host. The encapsulated cells naturally or are bioengineered to continuously secrete therapeutic amounts of pharmaceuticals useful to treat ocular conditions.
The manufacture of spherical or tubular capsules has been disclosed in previous patents, such as U.S. Pat. No. 583,187. The tubular capsules are preferred because fine tubes can be coiled, twisted or otherwise deposited in various shapes to provide configurations that are appropriate for specific anatomical structures. Furthermore the tubular structure allows easy removal when needed. A detailed description of tubular capsule construction is disclosed in U.S. Pat, No. 5,283,187, which is incorporated herein by reference. Various polymers, such as polyacrylates (including acrilic copolymers) polyvinylidienes, polyurethahes, polystyrenes, polyamides, cellulose, acetates, celluose nitrates, polysulfones, polyacrylonitriles, as well as derivatives, copolymers, and mixtures thereof, can be used to form the membrane coatings of the capsules;
Many classes of compounds, when applied to the eye, are known to lower IOP. Examples include acetylcholine, epinephrine, prostaglandins, natriuretic peptides and endothelins (Kaufman, et al., “Medical Therapy of Glaucoma,” Glaucoma, (eds.) P. L. Kaufman and T. W. Mittag, Mosby Publishing Co, pp. 9.7-9.30, 1991; Takashima, et al., “Effects of Natriuretic Peptide Family on Intraocular Pressure of Rabbit Eyes,”
Invest. Ophthalmol. Vis. Sci
., 36: S734, 1995; and MacCumber, et al., “Ocular Effects of the Endothelins.” Arch. Ophthalmol., 109:705-709, 1991). Thus, cells that naturally or are artificially transformed to secrete therapeutic amounts of these compounds will be useful in lowering IOP when encapsulated and implanted in the anterior chamber of the eye.
An example of cells naturally secreting IOP-lowering substance is the adrenal chromaffin celi, which is known to secrete epinephrine (Calve, et al., “Catecholarnine Secretion, Calcium Levels and Calcium Influx in Response to Membrane Depolarization in Bovine Chromaffin Cells,”
Neuroscience,
68:265-272, 1995; and Garcia, et al., “High-Performance Liquid Chromatographic Determination of Norepinephrine, Epinephrine, and Doparmine in Human Foetal Adrenal Gland.”
J. Chrontatogr B. Bionied. Appl.,
656:77-80, 1994). Hence, bovine or human fetal adrenal chromaffin cells (or other epinephrine-secreting cells) encapsulated and implanted in the anterior chamber of the eye may be useful in the treatment of ocular hypertension. The amount of cells implanted should be sufficient to produce 0.1 to 100 &mgr;moles of epinephrine every day, preferably between 1 to 10 &mgr;moles day.
Another example of cells naturally secreting IOP-lowering substance is the endometrium epithelial cell, which is known to secrete a high amount of prostaglandin F
2a
(Kim. et al., “Cell Type Specificity and Protein Kinase C Dependency on the Stimulation of Prostaglandin E
2
and Prostaglandin F
2a
Production by Oxytocin and Platelet-Activating Factor in Bovine Endometrial Cell.”
J. Repiodiciion anid Fertility
, 103:239-247, 1995). Hence, bovine endometrium epithelial cells (or other prostaglandin F
2a
-secreting cells) encapsulated and implanted in the anterior chamber of the eye maybe useful in the treatment of ocular hypertension. The amount of cells implanted should be sufficient to produce 1 to 1000 nmoles of prostaglandin F
2a
every day, preferably between 10 to 100 nmoles/day.
For other IOP-lowering substances, where naturally secreting cells are not readily available, molecular biological techniques can be used to bioengineer an appropiate cell line to induce a continuous production and release of the compound of interest. For example a preferred compound of interest for IOP-lowering is acetylcholine. Acetylcholine is synthesized in the cell in a one-step reaction by choline acetyltransferase (ChAT; acetyl-CoA:choline O-acetyltransferase, EC 2.3.1.6). Stably transfected cells expressing ChAT cDNA will increase their acetylcholine synthesis and release. Numerous procedures are known to achieve the cloning and expression of cDNA and genomic DNA for ChAT in various cell lines. For example, Misawa and colleagues (Misawa, et al., “Calcium-Independent Release of Acetylcholine From Stable Cell Lines Expressing Mouse Choline Acewltransferase cDNA.”
J. Neurochem
., 62:465-470, 1994) demonstrated procedures for the c
Alcon Manufacturing Ltd.
Flood Michele C.
Tate Christopher R.
Yeager Sally S.
LandOfFree
Methods for treating ocular diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating ocular diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating ocular diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2934774